#United States #Chicago #Bantam Pharmaceutical #BTM-3566 #FAM210B

Bantam Pharmaceutical Unveils Promising Preclinical Results for BTM-3566

Bantam Pharmaceutical, a pioneering company in drug discovery focusing on cancer treatments, shared crucial preclinical findings for its leading candidate BTM-3566 during the American Association for Cancer Research (AACR) Annual Meeting on April 25-30, 2025. The conference took place at the McCormick Place Convention Center in Chicago, highlighting innovative advances in cancer research.

Key Findings from the Data

The data presented offered strong evidence of BTM-3566's efficacy in inducing solid tumor regression across various cancer models. Furthermore, the research introduced FAM210B, a mitochondrial protein, as a potential biomarker for predicting treatment response in patients.

BTM-3566 is a first-in-class small molecule therapeutic designed to target a challenging segment of aggressive tumors by activating the OMA1-ATF4 Integrated Stress Response (ISR) pathway. Previous studies had indicated robust single-agent activity of BTM-3566 in cell line models and in patient-derived xenografts of mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL), regardless of the tumors’ cell of origin or genetic makeup. This new data expands its potential application to solid tumors, confirming its promising in vitro and in vivo activity.

Mechanism of Action and Treatment Implications

The new research underscores that BTM-3566 not only drives tumor regression but also demonstrates pronounced effects in solid tumor models exhibiting low FAM210B RNA expression. Importantly, experiments showed that the presence of FAM210B can significantly block the drug's efficacy across multiple tumor models, suggesting that this protein plays a critical mechanistic role in determining the response to BTM-3566.

Additionally, the drug showed encouraging additive and synergistic effects when combined with various approved cancer therapies, indicating the potential for incorporating BTM-3566 into multi-agent treatment plans that could enhance overall effectiveness against aggressive tumors.

Insights from Bantam's Leadership

Michael Stocum, President and CEO of Bantam Pharmaceutical, emphasized the importance of these findings, stating, “Our data not only highlights the unique mechanism of action of BTM-3566 but also opens avenues for patient selection based on FAM210B expression. We are optimistic about the compounding possibilities this has for patient treatment, especially as we continue to explore its use in combination with other cancer drugs.”

Experience at AACR 2025

The poster presentation was titled, “Selective pharmacological activation of the mitochondrial protease OMA1 inhibits tumor growth and induces regression in tumors expressing low levels of FAM210B,” and was led by Dr. Matthew Kostura, Chief Scientific Officer at Bantam Pharmaceutical. This session on Experimental and Molecular Therapeutics took place on April 28, highlighting the ongoing commitment of Bantam to harness mitochondrial dynamics in cancer therapy.

Future Directions

Bantam is committed to advancing BTM-3566 through ongoing clinical trials, currently in a Phase 1 study evaluating its effectiveness in relapsed or refractory mature B-cell lymphomas across the U.S. and Canada. These robust preclinical results position BTM-3566 for expanded studies into solid tumors, aiming to provide new treatment options for patients facing aggressive cancers that lack effective therapies.

For further details on the clinical trial, interested parties can visit ClinicalTrials.gov and search for NCT06792734. The full presentation will also be made available on the Bantam website soon after the conference.

Conclusion

Bantam Pharmaceutical's BTM-3566 holds tremendous promise not only as a standalone therapy but also as a component in combination strategies, potentially addressed via patient-specific biomarkers like FAM210B. The expanding landscape of treatment options delivered through innovative research could significantly improve outcomes for cancer patients in the near future.